Comparative Pharmacology
Head-to-head clinical analysis: RECORLEV versus THYROLAR 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RECORLEV versus THYROLAR 3.
RECORLEV vs THYROLAR-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
150 mg orally twice daily with a high-fat meal.
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
None Documented
None Documented
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged.
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone